Iqvia (IQV) Stock
Global provider of clinical research services and extensive data. Here's the price, business snapshot, and what's worth knowing about Iqvia in August 2026.
IQVIA Holdings Inc. (IQV) is a global provider of clinical research services, real-world data, and analytics to the life sciences industry. It operates as a contract research organisation (CRO) delivering clinical trial management, regulatory support and commercial analytics, combining operational trial capabilities with large proprietary healthcare datasets and technology platforms. The business benefits from structural trends: pharmaceutical and biotech firms outsourcing R&D, rising demand for real-world evidence and use of analytics/AI to shorten time-to-market. With a market capitalisation around $37.2bn, IQVIA’s scale and global footprint are competitive advantages, though growth depends on contract wins, regulatory trends and continued tech investment. Key risks include competitive pressure, project concentration, regulatory and data-privacy challenges, and sensitivity to R&D budgets. This summary is for general educational purposes only and not personal investment advice; values can fall as well as rise and investors should check current filings and suitability for their circumstances.
Why It’s Moving
IQVIA’s upbeat quarter, higher guidance, and fresh partnerships are keeping the stock in focus.
- IQVIA’s latest quarter topped Wall Street expectations, with stronger-than-expected revenue and adjusted EPS, which reinforced confidence that demand for its data and clinical research services is holding up.
- Management raised full-year 2026 revenue guidance and paired it with a new $2 billion share-repurchase program, signaling stronger cash generation and a more shareholder-friendly capital plan.
- The company also drew attention this month with a high-profile Medera partnership in cardiac gene therapy and a new No. 1 ranking from Everest Group, both of which supported the view that IQVIA’s platform is gaining strategic momentum.
IQVIA’s upbeat quarter, higher guidance, and fresh partnerships are keeping the stock in focus.
- IQVIA’s latest quarter topped Wall Street expectations, with stronger-than-expected revenue and adjusted EPS, which reinforced confidence that demand for its data and clinical research services is holding up.
- Management raised full-year 2026 revenue guidance and paired it with a new $2 billion share-repurchase program, signaling stronger cash generation and a more shareholder-friendly capital plan.
- The company also drew attention this month with a high-profile Medera partnership in cardiac gene therapy and a new No. 1 ranking from Everest Group, both of which supported the view that IQVIA’s platform is gaining strategic momentum.
Sixth Month Growth Performance
next-earnings-question
The next earnings date for IQV is expected to be October 27, 2026. It should cover Q3 2026 results. This timing matches the company’s typical late-October reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying IQVIA's stock, with a target price suggesting potential growth opportunities.
Financial Health
IQVIA is generating strong revenue and cash flow, indicating good financial performance and stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Research Demand
Outsourcing of drug development supports recurring project flow and long contract cycles, though revenues can vary with client R&D budgets and competitive pressures.
Global Footprint
A wide international presence helps win multinational trials and diversify revenues, but exposes the company to regulatory and currency headwinds.
Data and Analytics
Proprietary datasets and analytics platforms are differentiators as life sciences firms seek real‑world evidence and AI‑driven insights, though data governance is an ongoing risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
